Connexion
M'inscrire

Votre recherche

Filtres

Project précédent
Projet suivant
Nous verifions auprès de chaque centre si des nouvelles informations sont disponibles

R668-ALG-16114

Study in pediatric subjects with peanut allergy to evaluate efficacy and safety of dupilumab as adjunct to ar101 (peanut oral immunotherapy)
Source : Importé depuis le centre

Référence clinicaltrials.gov: NCT03682770
Peanut Allergy
Recrutement fermé
Dernière modification : 2024/02/11
Type de recherche

Interventionnel

Médicament expérimental

Phase 2


Population cible

Condition médicale (spécialité visée)

Choix aire thérapeutique

Peanut Allergy

Source : Importé depuis le centre

Profil des participants

Sexe(s) des participants

All

Source : Importé depuis le centre

Critères de sélection

Critères d'inclusion

Key Inclusion Criteria:

Experience dose-limiting symptoms at or before the challenge dose of peanut protein on screening and not experiencing dose-limiting symptoms to placebo as defined in the protocol
Serum Immunoglobulin E (IgE) to peanut of ≥10 kUA/L and/or a skin prick test (SPT) to peanut ≥8 mm compared to a negative control
Participants/legal guardians must be trained on the proper use of the epinephrine autoinjector device to be allowed to enroll in the study
Participants with other known food allergies must agree to eliminate these other food items from their diet so as not to confound the safety and efficacy data from the study

Key Exclusion Criteria:

History of other chronic disease (other than asthma, Atopic Dermatitis (AD), or allergic rhinitis) requiring therapy (eg, heart disease, diabetes, hypertension) that would represent a risk to participant's health or safety in this study or ability to comply with study protocol
History of frequent or recent severe, life-threatening episode of anaphylaxis or anaphylactic shock
History of eosinophilic Gastrointestinal (GI) disease

Asthma at time of enrollment with any of the following:

Forced Expiratory Volume 1 Second (FEV1) <80% of predicted or ratio of FEV1 to forced vital capacity (FEV1/FVC) <75% of predicted with or without controller medications
Inhaled corticosteroids (ICS) dosing of daily fluticasone (or equivalent ICS based on NHLBI dosing chart)
One hospitalization in the past year for asthma
Emergency room visit for asthma within 6 months prior to screening
Use of systemic corticosteroids within 2 months prior to screening
Use of other forms of allergen immunotherapy or immunomodulatory therapy within 3 months prior to screening
Use of any agents known or likely to interact with epinephrine (eg, beta-blockers, angiotensin converting enzyme-inhibitors, tri-cyclic antidepressants, or other drugs), within 3 weeks prior to screening
Allergy to oat (placebo in DBPCFC)

Note: Other protocol Inclusion/Exclusion Criteria apply

Source : Importé depuis le centre

Thérapie ou Intervention proposée

Cohortes
dupilumab + AR101
État du recrutement
unknown
placebo matching dupilumab + AR101
État du recrutement
unknown
Données à jour depuis : 11 février 2024

Description de l'étude

Résumé de l'étude

Primary objective is to assess whether dupilumab as adjunct to AR101 compared to placebo improves desensitization at the completion of up-dosing, defined as an increase in the proportion of participants who pass a post up-dosing double-blind placebo-controlled food challenge (DBPCFC) at visit 16.

Secondary objectives are:

To assess whether dupilumab as adjunct to AR101 compared to placebo improves desensitization at the completion of up-dosing, defined as an increase in the cumulative tolerated dose (log transformed) of peanut protein during a post up-dosing DBPCFC at visit 16
To assess whether dupilumab as (indefinite [continuously]) adjunct to AR101 compared to placebo maintains desensitization, defined as an increase in the proportion of participants who pass a post maintenance DBPCFC at visit 22
To assess whether dupilumab as (limited [previously]) adjunct to AR101 compared to placebo maintains desensitization, defined as an increase in the proportion of participants who pass a post maintenance DBPCFC at visit 22
To evaluate the safety and tolerability of dupilumab as adjunct to AR101 compared to placebo
To assess the effect of dupilumab (compared to placebo) as adjunct to AR101 on the change in peanut-specific Immunoglobulin E (sIgE), Immunoglobulin G (IgG), Immunoglobulin G4 (IgG4), and peanut-specific IgG4/IgE ratio
To assess if dupilumab increases the tolerability of AR101 as measured by the daily symptoms (electronic diary [e-diary]) during the up-dosing phase

Source : Importé depuis le centre

Sites

Centres participants

    10 affichés sur 24 centres
  • REGENERON INVESTIGATIONAL SITE

    Philadelphia

    PENNSYLVANIA, UNITED STATES

    Recrutement local
    État du recrutement: FERMÉ
  • REGENERON INVESTIGATIONAL SITE

    Chapel hill

    NORTH CAROLINA, UNITED STATES

    Recrutement local
    État du recrutement: FERMÉ
  • REGENERON INVESTIGATIONAL SITE

    New york

    NEW YORK, UNITED STATES

    Recrutement local
    État du recrutement: FERMÉ
  • REGENERON INVESTIGATIONAL SITE

    Great neck

    NEW YORK, UNITED STATES

    Recrutement local
    État du recrutement: FERMÉ
  • REGENERON INVESTIGATIONAL SITE

    Ocean township

    NEW JERSEY, UNITED STATES

    Recrutement local
    État du recrutement: FERMÉ
  • REGENERON INVESTIGATIONAL SITE

    Minneapolis

    MINNESOTA, UNITED STATES

    Recrutement local
    État du recrutement: FERMÉ
  • REGENERON INVESTIGATIONAL SITE

    Ypsilanti

    MICHIGAN, UNITED STATES

    Recrutement local
    État du recrutement: FERMÉ
  • REGENERON INVESTIGATIONAL SITE

    Ann arbor

    MICHIGAN, UNITED STATES

    Recrutement local
    État du recrutement: FERMÉ
  • REGENERON INVESTIGATIONAL SITE

    Boston

    MASSACHUSETTS, UNITED STATES

    Recrutement local
    État du recrutement: FERMÉ
  • REGENERON INVESTIGATIONAL SITE

    Seattle

    WASHINGTON, UNITED STATES

    Recrutement local
    État du recrutement: FERMÉ

Dernière modification : 11 février 2024
Données à jour depuis : 11 fév.
Origine des données : clinicaltrials.gov
Référence clinicaltrials.gov: NCT03682770